Suppr超能文献

新型抗癫痫药物左乙拉西坦在小鼠、大鼠、兔和犬体内的比较药代动力学及代谢研究

Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog.

作者信息

Benedetti M Strolin, Coupez R, Whomsley R, Nicolas J M, Collart P, Baltes E

机构信息

UCB S. A., Pharma Sector, Department of Global Product Safety and Metabolism, 21 rue de Neuilly, F-92003 Nanterre, France.

出版信息

Xenobiotica. 2004 Mar;34(3):281-300. doi: 10.1080/0049825042000196749.

Abstract

1: The pharmacokinetics and metabolism of 14C-levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog after a single oral dose were investigated. Moreover, the in vitro hydrolysis of levetiracetam to its major carboxylic metabolite by rat tissue homogenates was investigated to identify tissues involved in the production of the metabolite. Data are also presented on the induction of the enzyme(s) involved in levetiracetam hydrolysis in the rat. 2: Levetiracetam was rapidly and almost completely absorbed. The unchanged drug accounted for a very high percentage of plasma radioactivity. Levetiracetam did not bind to plasma proteins. Although brain radioactivity concentrations were lower than those of whole blood at early time points, brain-to-blood ratios increased over time. The predominant route of elimination of total 14C was excretion via urine, accounting for about 81, 93, 87 and 89% of the dose in the mouse, rat, rabbit and dog, respectively. Consequently, levetiracetam was poorly metabolized. It was submitted in vivo to hydrolysis and/or oxidation. Hydrolysis of the amide function of levetiracetam produced the corresponding acid. However, levetiracetam could also be oxidized at positions 3 and 4 of the 2-oxopyrrolidine ring. Finally, the compound and the corresponding acid metabolite could be oxidized at position 5 of the 2-oxopyrrolidine ring and then hydrolysed with the opening of the ring. 3: All the investigated rat tissues (liver, kidney, lung, brain, small intestine mucosa) had the potential to produce the acid metabolite. By contrast, the acid was undetectable following incubation of levetiracetam with buffer alone or heat-denaturated liver fractions. 4: No marked species or sex differences were observed in the absorption, disposition and metabolism of levetiracetam. 5:The hydrolysis of levetiracetam is carried out by an enzymatic process characterized by a broad tissue distribution. In the rat, the enzyme system hydrolysing levetiracetam is not induced by phenobarbital, at least under the experimental conditions used herein, whereas the enzyme system(s) involved in the other metabolic pathways is induced.

摘要

1: 研究了新型抗癫痫药14C-左乙拉西坦单次口服给药后在小鼠、大鼠、兔子和狗体内的药代动力学及代谢情况。此外,还研究了大鼠组织匀浆将左乙拉西坦体外水解为其主要羧酸代谢物的过程,以确定参与该代谢物生成的组织。同时也给出了大鼠体内参与左乙拉西坦水解的酶的诱导情况的数据。2: 左乙拉西坦吸收迅速且几乎完全吸收。原形药物在血浆放射性中占比非常高。左乙拉西坦不与血浆蛋白结合。尽管在早期时间点脑放射性浓度低于全血,但脑血比随时间增加。总14C的主要消除途径是经尿液排泄,在小鼠、大鼠、兔子和狗中分别占给药剂量的约81%、93%、87%和89%。因此,左乙拉西坦代谢较差。它在体内会发生水解和/或氧化。左乙拉西坦酰胺官能团的水解产生相应的酸。然而,左乙拉西坦也可在2-氧代吡咯烷环的3位和4位被氧化。最后,该化合物及其相应的酸代谢物可在2-氧代吡咯烷环的5位被氧化,然后环打开并水解。3: 所有研究的大鼠组织(肝脏、肾脏、肺、脑、小肠黏膜)都有产生酸代谢物的潜力。相比之下,左乙拉西坦单独与缓冲液或热变性肝脏组分孵育后未检测到酸。4: 在左乙拉西坦的吸收情况、处置和代谢方面未观察到明显的物种或性别差异。5: 左乙拉西坦的水解是通过一种具有广泛组织分布特征的酶促过程进行的。在大鼠中,至少在本文所用的实验条件下,水解左乙拉西坦的酶系统不受苯巴比妥诱导,而参与其他代谢途径的酶系统会被诱导。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验